Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at firstname.lastname@example.org and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
Abivax, an emissary of Cuba's well-regarded but closed-off biotech sector, is raising money to fund clinical trials of a hepatitis B vaccine. The vaccine was discovered by Cuba's Center for Genetic Engineering and Biotechnology and is now on the cusp of making the leap from the island to the wider world.
Australian biotech Regeneus is set to become the latest company to brave moving a personalized cancer vaccine into the clinic. The company picked up clearance from an ethics committee this week, clearing the last remaining obstacle between it and the start of an early-phase study.
Pharmacies continue push to lower barriers to seasonal flu vaccination
In the years since the H1N1 pandemic, pharmacies have established themselves as major providers of vaccines, with Walgreens and CVS administering jabs to more than 10 million people last year. But while anything that makes it easier for patients to get vaccinated is welcomed by public health officials and manufacturers, physicians have reservations about pharmacies stepping onto their turf.
The debate around use of Merck's Gardasil in the United Kingdom is ratcheting up ahead of a meeting of the Joint Committee on Vaccinations and Immunisation (JCVI) in October.
Accidental poliovirus dump adds to GSK's production woes
Having begun the month by revealing new problems at its Canadian flu vaccine plant and followed that up with a fine for violating the U.S. Clean Air Act last week, GSK has now accidentally dumped live poliovirus into the Belgian sewer system.
Measles outbreaks in New York and Canada have ratcheted up arguments about the merits of vaccines in recent weeks, but the row is perhaps most intense in Colorado. This week a proposal to tighten vaccine exemption laws advanced in the state, leading to opponents accusing the bill's sponsor of treating parents like "idiots" and "morons."
Buzz: Baxter is considering selling its vaccine unit
Baxter is looking into selling its vaccine business, Reuters reports. The process is at an early stage, with Baxter having recently tapped Goldman Sachs to advise and begun contacting potential buyers, including private equity firms.
Government H5N1 vaccine orders drive jump in sales at Sinovac
At the start of 2014 the Chinese vaccine sector was rocked by the failure of three leading suppliers to obtain good manufacturing practice certification. Sinovac Biotech escaped unscathed from the rule tightening and this week posted a 17% jump in fourth-quarter sales.
PhIII fail further dents hopes for GSK's cancer vaccine
Last month GlaxoSmithKline CEO Andrew Witty gave an upbeat assessment of the prospects of the MAGE-A3 cancer vaccine, with the executive saying the product has several chances to succeed. Now it has one fewer after the vaccine missed its primary endpoints in a Phase III lung cancer trial.
Going into 2014 Novartis said this was the year Bexsero, the great hope of its struggling vaccine unit, would begin to generate significant sales. Exactly how significant depends on whether governments agree to pay for the vaccine, and in this regard Novartis received a big boost this week. Britain could begin vaccinating all babies with Bexsero as early as this summer.